Barclays
EGRX

Barclays’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Barclays’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,233
Closed -$7.12K – 5695
2024
Q4 		$7.12K Sell
14,233
-810
-5% -$2.31K ﹤0.01% 5029
2024
Q3 		$56.1K Sell
15,043
-4,066
-21% -$19.4K ﹤0.01% 4720
2024
Q2 		$107K Sell
19,109
-3,481
-15% -$15.2K ﹤0.01% 3872
2024
Q1 		$118K Sell
22,590
-6,993
-24% -$38.4K ﹤0.01% 4374
2023
Q4 		$155K Buy
29,583
+18,961
+179% +$187K ﹤0.01% 4518
2023
Q3 		$168K Sell
10,622
-14,548
-58% -$261K ﹤0.01% 3380
2023
Q2 		$489K Buy
25,170
+19,600
+352% +$465K ﹤0.01% 2766
2023
Q1 		$158K Sell
5,570
-28,825
-84% -$856K ﹤0.01% 3930
2022
Q4 		$1.01M Sell
34,395
-4,418
-11% -$140K ﹤0.01% 2793
2022
Q3 		$1.03M Buy
38,813
+35,373
+1,028% +$1.3M ﹤0.01% 2210
2022
Q2 		$153K Sell
3,440
-5,738
-63% -$264K ﹤0.01% 3577
2022
Q1 		$455K Sell
9,178
-5,748
-39% -$276K ﹤0.01% 2965
2021
Q4 		$759K Buy
14,926
+3,149
+27% +$163K ﹤0.01% 2994
2021
Q3 		$657K Buy
11,777
+5,407
+85% +$266K ﹤0.01% 3037
2021
Q2 		$273K Sell
6,370
-17,557
-73% -$724K ﹤0.01% 3413
2021
Q1 		$998K Sell
23,927
-1,605
-6% -$74.5K ﹤0.01% 2784
2020
Q4 		$1.19M Sell
25,532
-2,828
-10% -$132K ﹤0.01% 2633
2020
Q3 		$1.2M Buy
28,360
+14,614
+106% +$639K ﹤0.01% 2525
2020
Q2 		$659K Sell
13,746
-24,351
-64% -$1.21M ﹤0.01% 3106
2020
Q1 		$1.75M Buy
38,097
+16,393
+76% +$823K ﹤0.01% 2406
2019
Q4 		$1.3M Sell
21,704
-13,846
-39% -$826K ﹤0.01% 3426
2019
Q3 		$2.01M Buy
35,550
+4,781
+16% +$269K ﹤0.01% 2860
2019
Q2 		$1.71M Buy
30,769
+3,608
+13% +$188K ﹤0.01% 3103
2019
Q1 		$1.37M Buy
27,161
+6,022
+28% +$268K ﹤0.01% 3044
2018
Q4 		$852K Sell
21,139
-6,951
-25% -$358K ﹤0.01% 3287
2018
Q3 		$1.95M Buy
28,090
+17,302
+160% +$1.31M ﹤0.01% 2913
2018
Q2 		$817K Buy
10,788
+6,242
+137% +$393K ﹤0.01% 3493
2018
Q1 		$238K Sell
4,546
-13,737
-75% -$799K ﹤0.01% 4681
2017
Q4 		$976K Buy
18,283
+17,276
+1,716% +$961K ﹤0.01% 3137
2017
Q3 		$60K Sell
1,007
-28,462
-97% -$1.72M ﹤0.01% 5258
2017
Q2 		$2.33M Sell
29,469
-15,024
-34% -$1.23M ﹤0.01% 2112
2017
Q1 		$3.69M Buy
44,493
+10,654
+31% +$792K ﹤0.01% 1551
2016
Q4 		$2.68M Sell
33,839
-30,826
-48% -$2.24M ﹤0.01% 1887
2016
Q3 		$4.53M Buy
64,665
+62,690
+3,174% +$3.47M 0.01% 1383
2016
Q2 		$77K Sell
1,975
-400
-17% -$16.7K ﹤0.01% 4576
2016
Q1 		$95K Sell
2,375
-337
-12% -$21.4K ﹤0.01% 4394
2015
Q4 		$238K Buy
2,712
+2,452
+943% +$194K ﹤0.01% 3770
2015
Q3 		$19K Buy
260
+96
+59% +$7.99K ﹤0.01% 5489
2015
Q2 		$13K Sell
164
-19,836
-99% -$1.29M ﹤0.01% 5956
2015
Q1 		$820K Buy
+20,000
New +$567K ﹤0.01% 3156
2014
Q4 		– Sell
-42
Closed -$1K – 7665
2014
Q3 		$1K Sell
42
-9,131
-100% -$113K ﹤0.01% 7545
2014
Q2 		$128K Buy
9,173
+9,082
+9,980% +$104K ﹤0.01% 5225
2014
Q1 		$1K Buy
+91
New +$1.24K ﹤0.01% 7498

Other funds holding EGRX

SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Barclays's EGRX Position: Q1 2025 in Review

Barclays sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2025, closing a stake of 14,233 shares — an estimated $7.12K sold.

Barclays first reported a position in EGRX in Q1 2014 and held it in 43 quarters. The position peaked at $4.53M in Q3 2016. 2 funds tracked by Wall St. Rank hold EGRX as of Q1 2025.

  • Barclays reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2025 after selling out during the quarter.
  • Barclays sold 14,233 Eagle Pharmaceuticals, Inc. shares in Q1 2025, an estimated $7.12K.
  • Barclays first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 43 quarters.
  • Barclays's Eagle Pharmaceuticals, Inc. position peaked at $4.53M in Q3 2016.
  • 2 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2025.

Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.